Review
Biochemistry & Molecular Biology
Alen Roncevic, Nenad Koruga, Anamarija Soldo Koruga, Robert Roncevic, Tatjana Rotim, Tihana Simundic, Domagoj Kretic, Marija Peric, Tajana Turk, Damir Stimac
Summary: Glioblastoma (GBM) is a highly aggressive glial tumor in the central nervous system. Current standard treatments only offer a median survival of 15 months. Tissue samples obtained during surgery are crucial for GBM diagnosis, and there is significant room for improvement in the current treatment methods.
Review
Biochemistry & Molecular Biology
Alejandro Rodriguez-Camacho, Jose Guillermo Flores-Vazquez, Julia Moscardini-Martelli, Jorge Alejandro Torres-Rios, Alejandro Olmos-Guzman, Cindy Sharon Ortiz-Arce, Dharely Raquel Cid-Sanchez, Samuel Rosales Perez, Monsserrat Del Sagrario Macias-Gonzalez, Laura Crystell Hernandez-Sanchez, Juan Carlos Heredia-Gutierrez, Gabriel Alejandro Contreras-Palafox, Jose de Jesus Emilio Suarez-Campos, Miguel Angel Celis-Lopez, Guillermo Axayacalt Gutierrez-Aceves, Sergio Moreno-Jimenez
Summary: Glioblastoma is a lethal tumor with limited treatment options. Efforts are being made in various research areas to find new therapies that can improve patient survival and quality of life.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Nasser K. Yaghi, Mark R. Gilbert
Summary: This review examines the challenges faced by immunotherapies in treating glioblastoma, explores current treatment options, and proposes future directions for GBM immunotherapy.
Article
Cell Biology
I-Cheng Lin, Chih-Hui Chang, Yoon Bin Chong, Shih-Hsun Kuo, Yu-Wen Cheng, Ann-Shung Lieu, Tzu-Ting Tseng, Chien-Ju Lin, Hung-Pei Tsai, Aij-Lie Kwan
Summary: This study demonstrates that NUCB2 expression is closely associated with prognosis and tumor progression in GBM patients, with knockdown of NUCB2 leading to reduced cell viability and invasion ability in GBM cells. Overexpression of NUCB2 influences the sensitivity of GBM cells to chemotherapy and radiotherapy, and targeting NUCB2 protein expression may offer a novel therapeutic approach for GBM treatment.
Review
Pharmacology & Pharmacy
Wei Wu, Jessica L. Klockow, Michael Zhang, Famyrah Lafortune, Edwin Chang, Linchun Jin, Yang Wu, Heike E. Daldrup-Link
Summary: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor with highly infiltrative nature and treatment resistance, highlighting the importance of innovative treatment strategies. The standard treatment for GBM is surgical resection followed by chemoradiotherapy, but the robust DNA repair and self-renewing capabilities of GBM cells lead to resistance against current therapies.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Biotechnology & Applied Microbiology
Amal Marie, Ahmed Maklad, Abdullah AlTwairgi, Moemen Aly, Ashraf Elyamany, Wafaa AlShaqweer, Mohamed Senosy, Ali Balbaid
Summary: Management of elderly patients with GBM is controversial. The study found that conventional radiotherapy and completion of adjuvant chemotherapy were associated with better overall survival (OS), while early start of adjuvant treatment and completion of adjuvant chemotherapy were associated with better progression-free survival (PFS).
ONCOTARGETS AND THERAPY
(2022)
Review
Biochemistry & Molecular Biology
Qixiong Lu, Xiaoyang Lu, Yuansheng Zhang, Wei Huang, Hu Zhou, Tao Li
Summary: Ferroptosis is a form of cell death characterized by excessive iron-dependent lipid peroxidation. It disrupts the cellular antioxidant capacities and leads to oxidative overload and cell death. Ferroptosis plays a significant role in various diseases.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2023)
Article
Health Care Sciences & Services
Fabiana Gregucci, Alessia Surgo, Ilaria Bonaparte, Letizia Laera, Maria Paola Ciliberti, Roberta Carbonara, Maria Annunziata Gentile, David Giraldi, Roberto Calbi, Morena Caliandro, Nicola Sasso, Salvatore D'Oria, Carlo Somma, Gaetano Martinelli, Giammarco Surico, Giuseppe Lombardi, Alba Fiorentino
Summary: This study aimed to evaluate the efficacy and toxicity of Hypo-RT with SIB in combination with TMZ in poor-prognosis GBM patients. Among 30 patients, 25 were evaluated with a minimum follow-up of 6 months, showing that the treatment was effective and safe, with no severe neurological side effects but some cases of grade 3-4 hematologic toxicity.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Immunology
Yang Fan, Zijie Gao, Jianye Xu, Huizhi Wang, Qindong Guo, Hao Xue, Rongrong Zhao, Xing Guo, Gang Li
Summary: This study reveals the role of small nucleolar RNA host genes (SNHGs) in glioblastoma (GBM) subtypes, tumor microenvironment (TME) infiltration, and stemness characteristics. By generating the SNHGscore model, it was found that the high SNHGscore group had a poor prognosis, the mesenchymal (MES) subtype, infiltration of suppressive immune cells, and a differentiated phenotype. Furthermore, high SNHGscore was associated with a weaker response to anti-PD-1/L1 immunotherapy and tumor cells with high SNHG scores were more sensitive to drugs targeting the EGFR and ERK-MAPK signaling pathways. Additionally, the universality of SNHG interaction patterns was verified in multiple cancers, highlighting the potential clinical utility for cancer therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Zhen Wang, Xiang-long Tang, Meng-jie Zhao, Yi-ding Zhang, Yong Xiao, Yu-yang Liu, Chun-fa Qian, Yan-dong Xie, Yong Liu, Yuan-jie Zou, Kun Yang, Hong-yi Liu
Summary: In order to overcome the challenges of using RNA interference (RNAi) therapy for glioblastoma (GBM), researchers developed a cancer cell membrane (CCM)-disguised hypoxia-triggered RNAi nanomedicine for siRNA delivery. This nanomedicine showed prolonged blood circulation, efficient blood-brain barrier transcytosis, and specific accumulation in GBM sites. By silencing the PGK1 gene and enhancing the effects of paclitaxel-induced chemotherapy and ionizing radiation, this RNAi nanomedicine effectively suppressed tumors in hypoxic regions. In summary, a biomimetic intelligent RNAi nanomedicine was developed to deliver siRNA and synergistically mediate combined chemo/radiotherapy for orthotopic GBM treatment.
JOURNAL OF NANOBIOTECHNOLOGY
(2023)
Review
Biotechnology & Applied Microbiology
Dhruba Dhar, Swachhatoa Ghosh, Soumen Das, Jyotirmoy Chatterjee
Summary: Glioblastoma multiforme (GBM) is the most aggressive and deadly form of brain cancer. The currently available treatment methods often fail to be successful, leading to rapid disease progression and short survival time. Magnetic nanoparticles (MNPs) show great potential in targeted treatment of GBM due to their unique physical features. This review discusses the limitations of current therapeutic strategies and the role of MNPs in overcoming these limitations, as well as recent advances and future directions of MNP-based theranostics for GBM.
Article
Multidisciplinary Sciences
Andrew J. Brenner, John Floyd, Lisa Fichtel, Joel Michalek, Kunal P. Kanakia, Shiliang Huang, David Reardon, Patrick Y. Wen, Eudocia Quant Lee
Summary: The study investigated the safety and efficacy of Evo in combination with bevacizumab for treating bevacizumab refractory glioblastoma patients. Results showed a median overall survival of approximately 4.6 months with a median time to disease progression of 53 days from best response. The progression free survival at 4 months (PFS-4) on Evo-Bev treatment demonstrated a statistically significant improvement.
SCIENTIFIC REPORTS
(2021)
Review
Clinical Neurology
Ruichong Ma, Martin J. B. Taphoorn, Puneet Plaha
Summary: Glioblastoma is the most common and malignant primary brain tumor in adults, with poor prognosis despite current standard therapy. However, advancements in surgical technology and understanding of the biology of GB have led to increased rates of safe maximal resection and identified potential targets for new treatments like immunotherapy.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2021)
Article
Multidisciplinary Sciences
Mahdie Mousavi, Fereshteh Koosha, Ali Neshastehriz
Summary: A novel nanocomplex, SPIO@AuNP-Cisplatin-Alginate (SACA), was synthesized and characterized. The combination of SACA and 6 MV X-ray significantly decreased the viability of U87MG cells and increased apoptosis, indicating that this nanocomplex effectively enhanced the radiosensitivity of cancer cells.
Article
Nanoscience & Nanotechnology
Baofeng Yun, Zhengpeng Gu, Zheng Liu, Yaobao Han, Qiao Sun, Zhen Li
Summary: The in situ generation of SO2 within a tumor can effectively reduce the chemo-/radioresistance of glioblastoma. By converting X-rays into ultraviolet rays, the prodrug S-amino-1,3-dihydrobenzo[c]thiophene 2,2-dioxide (ATD) loaded on scintillator nanoparticles generates SO2, which damages mitochondria, inhibits drug efflux, and reduces MGMT expression, leading to improved therapeutic efficacy against resistant tumors.
ACS APPLIED MATERIALS & INTERFACES
(2022)
Article
Oncology
A. Custodio, J. Moreno-Rubio, J. Aparicio, J. Gallego-Plazas, R. Yaya, J. Maurel, O. Higuera, E. Burgos, D. Ramos, A. Calatrava, E. Andrada, R. Lopez, V. Moreno, R. Madero, P. Cejas, J. Feliu
ANNALS OF ONCOLOGY
(2014)
Letter
Gastroenterology & Hepatology
Isidro Machado, Jesus Santos, Ana Calatrava, Julia Cruz, Fernando Martinez, Fernanda Maia de Alcantara, Antonio Barrasa, Ricardo Yaya, Carlos Fernandez-Martos, Jose Luis Mengual, Rafael Estevan
GASTROENTEROLOGIA Y HEPATOLOGIA
(2012)
Article
Oncology
A. Berrocal, P. Perez Segura, M. Gil, C. Balana, J. Garcia Lopez, R. Yaya, J. Rodriguez, G. Reynes, O. Gallego, L. Iglesias
JOURNAL OF NEURO-ONCOLOGY
(2010)
Article
Oncology
Ana Custodio, Juan Moreno-Rubio, Jorge Aparicio, Javier Gallego-Plazas, Ricardo Yaya, Joan Maurel, Nuria Rodriguez-Salas, Emilio Burgos, David Ramos, Ana Calatrava, Encarna Andrada, Esther Diaz-Lopez, Antonio Sanchez, Rosario Madero, Paloma Cejas, Jaime Feliu
MOLECULAR CANCER THERAPEUTICS
(2014)
Letter
Oncology
Ramon Martinez, Gabriele Schackert, Ricard Yaya-Tur, Inigo Rojas-Marcos, James G. Herman, Manel Esteller
JOURNAL OF NEURO-ONCOLOGY
(2007)
Article
Oncology
C Balaña, A López-Pousa, A Berrocal, R Yaya-Tur, A Herrero, JL García, J Martín-Broto, M Benavides, M Cerdá-Nicolás, R Ballester, J Balart, J Capellades
JOURNAL OF NEURO-ONCOLOGY
(2004)
Article
Oncology
MF Paz, R Yaya-Tur, I Rojas-Marcos, G Reynes, M Pollan, L Aguirre-Cruz, JL García-Lopez, J Piquer, MJ Safont, C Balaña, M Sanchez-Cespedes, M García-Villanueva, L Arribas, M Esteller
CLINICAL CANCER RESEARCH
(2004)
Article
Oncology
A Caraceni, E Zecca, C Bonezzi, E Arcuri, RY Tur, M Maltoni, M Visentin, G Gorni, C Martini, W Tirelli, M Barbieri, F De Conno
JOURNAL OF CLINICAL ONCOLOGY
(2004)
Article
Clinical Neurology
B Ortiz-Muñoz, A Menéndez-López, R Yayá-Tur, L Arribas-Alpuente, J Maíquez-Richart, M Bordes-Monmeneu
REVISTA DE NEUROLOGIA
(2003)
Article
Oncology
M Sanson, M Napolitano, R Yaya, F Keime-Guibert, P Broët, K Hoang-Xuan, JY Delattre
JOURNAL OF NEURO-ONCOLOGY
(2000)
Article
Oncology
E Verger, G Miguel, R Yaya, N Vinolas, S Villa, T Pujol, L Quinto, F Graus
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2005)